Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Mersana Therapeutics Inc (Mersana) is a clinical-stage biopharmaceutical company that focuses on developing novel antibody-drug conjugates (ADCs). Its activities carry out leveraging its proprietary ADC platforms to create innovative cancer treatments. The company's products include the Dolasynthen and Immunosynthen platforms, that are designed to deliver cytotoxic and immunostimulatory payloads, respectively. Mersana's pipeline products include XMT-1660, a B7-H4-targeting multiple solid tumors; XMT-2056, a Novel HER2 Epitope that treats multiple solid tumors, XMT-2068 and XMT-2175. The company operates across the US. Mersana is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
840 Memorial Dr, Cambridge, Massachusetts, 02139-3789
Website
www.mersana.com
Telephone
1 617 4980020
No of Employees
102
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$40.5M
Mersana Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| XMT-1660: Multiple Solid Tumors |
| XMT-2056: Multiple Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In January, the company was acquired by Day One Biopharmaceuticals, Inc., a biopharmaceutical company. |
| 2025 | Regulatory Approval | In January, the company announced the approval from the U.S. Food and Drug Administration for additional Fast Track designation to XMT-1660. |
| 2022 | Contracts/Agreements | In December, the company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA to discover novel Immunosynthen antibody drug conjugates. |
Competitor Comparison
| Key Parameters | Mersana Therapeutics Inc | Pfizer Inc | AstraZeneca Plc | AbbVie Inc | Takeda Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | Japan |
| City | Cambridge | New York City | Cambridge | North Chicago | Chuo-Ku |
| State/Province | Massachusetts | New York | Cambridgeshire | Illinois | Tokyo |
| No. of Employees | 102 | 81,000 | 94,300 | 55,000 | 47,455 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Mott | Chairman | Executive Board | 2012 | 59 |
| Martin Huber, MD | Director; President; Chief Executive Officer | Executive Board | 2023 | 65 |
| Brian C. DeSchuytner | Chief Operating Officer; Senior Vice President; Chief Financial Officer | Senior Management | 2023 | 47 |
| Timothy B. Lowinger, PhD | Chief Science Officer; Senior Vice President; Chief Technology Officer | Senior Management | 2019 | 61 |
| Alejandra Carvajal | Senior Vice President; Chief Legal Officer | Senior Management | 2021 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer